Pioglitazone is effective for long-term treatment of patients with nonalcoholic steatohepatitis (NASH) with prediabetes or type 2 diabetes. However, it is not clear how the presence of type 2 diabetes affects the drug's efficacy. We compared metabolic and histologic responses to pioglitazone in patients with NASH and prediabetes vs type 2 diabetes.
N onalcoholic steatohepatitis (NASH) has become a major public health problem in the United States and worldwide, and is associated with an increased incidence of cirrhosis, hepatocellular carcinoma, and liver transplantation. 1, 2 By unclear mechanisms, the presence of type 2 diabetes mellitus (T2DM) appears to increase the risk of developing NASH, and is associated with more progression to advanced fibrosis and hepatocellular carcinoma in this population. 3, 4 Despite the higher prevalence and more rapid disease progression in the setting of T2DM, there are no studies comparing the effects of pharmacologic treatments in patients with vs without T2DM.
Results from a recent study by our group in a cohort of patients with prediabetes or T2DM and biopsy-proven NASH reported that pioglitazone led to an approximately 60% histologic response. 5 However, in patients without T2DM in the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial, pioglitazone did not reach the primary histologic outcome, although 47% of patients did have resolution of NASH (P ¼ .001). 6 These results have led to a controversy as to whether pioglitazone is equally effective for patients with NASH with and without T2DM. Current guidelines do not recommend pioglitazone for patients with NASH without T2DM. 7, 8 Knowing whether there is histologic liver benefit in patients without T2DM is important because pioglitazone provides metabolic and cardiovascular benefits to this population. In the Actos Now for Prevention of Diabetes (ACT NOW) 9, 10 and Insulin Resistance Intervention After Stroke 11 studies, pioglitazone delayed the progression to T2DM among patients at high risk of developing the disease. The IRIS study also reported a significant reduction in cardiovascular events with pioglitazone. 12 Taken together, establishing a head-to-head comparison about the metabolic and histologic effects of pioglitazone in patients with NASH with and without T2DM could have major clinical implications for the management of these patients.
Patients and Methods

Subjects
In-depth details about recruitment and inclusion/ exclusion criteria can be found elsewhere 5 (ClinicalTrials.gov: NCT00994682). In summary, 101 patients were recruited from the general population of San Antonio, Texas, between 2008 and 2014. Patients between 18 and 70 years old, with prediabetes or T2DM, and biopsy-proven NASH were enrolled. The diagnosis of prediabetes or T2DM was based on prior history, and results from fasting plasma glucose, hemoglobin A1c, and an oral glucose tolerance test (OGTT), according to American Diabetes Association guidelines. 13 They were excluded if they had a history of high alcohol intake (!30 g/d in men or !20 g/d in women), any liver disease other than NASH (ie, viral hepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease, drug-induced hepatitis), type 1 diabetes, or a history of clinically significant renal, pulmonary, or heart disease.
Study Design
After approximately 4 weeks of run-in, when all baseline metabolic measurements were performed, patients were randomized to pioglitazone 30 mg/d (uptitrated to 45 mg/d after 2 months if well tolerated) or matched placebo for 18 months. All patients received lifestyle counseling and a hypocaloric diet (weightmaintaining diet reduced by 500 kcal daily). All procedures performed at baseline (liver magnetic resonance proton spectroscopy, euglycemic insulin clamp with glucose turnover measurements, OGTT, dual-energy absorptiometry, and liver biopsy) were repeated after 18 months of therapy. Eighty-three patients completed 18 months of follow-up and were included in longitudinal analyses. Patients were offered to continue in an 18-month, open-label phase with pioglitazone. An OGTT, dual-energy absorptiometry, and liver biopsy were repeated in patients completing 36 months of follow-up. The study was approved by the University of Texas Health Science Center at San Antonio Institutional Review Board and written informed consent was obtained from each patient before participation. All authors had access to the study data and reviewed and approved the final manuscript.
Euglycemic Hyperinsulinemic Clamp
A primed (25 mCi Â [fasting glucose/100])-continuous (0.25 mCi/min) infusion of 3-[ 3 H] glucose (DuPont-NEN, Boston, MA) was initiated and continued until the end of the study. During the last 30 minutes of the basal equilibration period (150-180 min), plasma samples were taken at 5-to 10-minute intervals for determination of plasma glucose, insulin concentrations, and 3-[ 3 H] glucose-specific activity. After the basal equilibration period, insulin was administered as a primed-continuous infusion at 10 mIU/(m 2 Â min) and 80 mIU/(m 2 Â min) for 120 minutes each, to assess suppression of endogenous (mainly hepatic) glucose production, suppression of free fatty acids (FFAs), and whole-body insulin-stimulated glucose disposal. A variable infusion of 20% dextrose was adjusted to maintain the plasma glucose concentration at approximately 90 to 100 mg/dL with a coefficient of variation <5%.
14
Hepatic Outcomes
The primary outcome was defined as a reduction in the nonalcoholic fatty liver disease activity score (NAS) ! 2 (from 2 different histologic categories), without any worsening of fibrosis. Secondary outcomes included resolution of NASH and improvement in individual histologic scores. Baseline biopsy specimens were first read by clinical pathologists to determine the inclusion of patients in the trial. At the end of the study, all biopsy specimens were re-assessed by an experienced research pathologist, who was blinded to all patient's identifiers, medication assignment, or pretreatment or posttreatment sequence. A diagnosis of definite NASH was made based on standard histologic criteria. 15 Localized proton nuclear magnetic resonance spectra of the liver were acquired on a Siemens TIM-Trio 3.0 T magnetic resonance image scanner (Siemens Healthcare, Erlangen, Germany) using methodology previously described. 16 A liver fat content of >5.56% was considered diagnostic of nonalcoholic fatty liver disease. 7 
Statistical Analysis
Data were summarized in percentages for categoric variables and as means AE SD for numeric variables. The chi-squared or the Fisher exact test were used for comparisons of categoric variables. For numeric variables, the Kruskal-Wallis or Student t test were performed for between-groups comparisons, and Wilcoxon matchedpairs signed-ranks test and a paired t test were performed for within-group comparisons (before vs after). To establish whether pioglitazone response was independent of diabetes status, 2-way analysis of variance (for numeric outcomes) and logistic regression (for categoric outcomes) were used. This was a post hoc analysis of the main study and no formal power calculation was performed a priori in the study design. However, we estimated a power of 0.67 to detect an absolute difference of 25% in the treatment effect of pioglitazone between patients with prediabetes and T2DM for the primary outcome (ie, 28% vs 53% based on the 41% treatment effect with pioglitazone in the entire cohort). This was increased to 0.83 by performing a pooled analysis including all patients from our 2 published randomized clinical trials with pioglitazone in NASH (total n ¼ 148).
5,17 A 2-tailed P value of less than .05 was considered statistically significant. Analyses were performed with Stata 11.1 (StataCorp LP, College Station, TX) and graphs with PRISM 6.0 (GraphPad Software, Inc, CA).
Results
Baseline Characteristics of Patients With and Without Type 2 Diabetes Mellitus
In Table 1 , we summarized the clinical and histologic characteristics of patients with NASH, dividing them based on the presence of prediabetes or T2DM. As can be observed, patients with T2DM were slightly older (54 AE 8 vs 47 AE 12 y; P ¼ .001), but were well matched with patients with prediabetes for sex, body mass index, and total body fat. As expected, patients with T2DM showed higher fasting plasma glucose levels (137 AE 31 vs 106 AE 8 mg/dL; P < .001), A1c levels (6.9% AE 1.0% vs 5.7% AE 0.5%; P < .001), and a trend toward higher fasting plasma insulin concentrations (15 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] vs 10 [6-16] mIU/mL; P ¼ .07) than patients with prediabetes. Insulin sensitivity was reduced in both groups at all tissue levels (liver, adipose tissue, and skeletal muscle), but more markedly among patients with T2DM. Intrahepatic triglyceride content was similar between both groups, and no differences were observed in plasma aspartate aminotransferase or alanine aminotransferase levels. However, patients with T2DM showed more severe inflammation (1.8 AE 0.5 vs 1.5 AE 0.5; P ¼ .004) and fibrosis (1.2 AE 1.1 vs 0.8 AE 0.9; P ¼ .039) when liver histology was assessed.
Changes in Histologic Outcomes After Pioglitazone Treatment
The primary outcome of the study (a reduction in the NAS of at least 2 points, with a reduction in at least 2 different categories, and without worsening of fibrosis) was similarly achieved by patients with prediabetes and patients with T2DM after pioglitazone treatment (60% vs 70%; P ¼ .51) ( Figure 1A ). This also translated into a similar treatment effect in both groups (difference between pioglitazone effect and that observed in the placebo group: 48% vs 46%). However, resolution of NASH after pioglitazone therapy only achieved statistical significance compared with placebo in patients with T2DM (60% vs 16%; P ¼ .002), but not in patients with prediabetes (55% vs 29%; P ¼ .12) ( Figure 1B) .
Overall, changes in the NAS after 18 months of pioglitazone therapy were similar for patients with T2DM and prediabetes (-1.3 AE 1.8 vs -1.2 AE 1.9, with no significant interaction between pioglitazone therapy and the presence of diabetes; P ¼ .72). All individual histologic parameters (steatosis, inflammation, ballooning, and fibrosis) showed a similar response after pioglitazone therapy when patients with T2DM and prediabetes were compared (all interaction terms between pioglitazone therapy and diabetes status were nonsignificant) ( Figure 2 ). However, when changes in fibrosis were assessed in more detail, we observed that only the group of patients with T2DM showed a significant improvement in fibrosis after 18 months of pioglitazone compared with placebo (-0.5 AE 0.9 vs 0.2 AE 1.2; P ¼ .042). This was not observed in patients with prediabetes (-0.4 AE 0.9 vs -0.2 AE 0.7; P ¼ .66). This difference was explained mainly by a different behavior in the placebo arms, with a trend toward faster progression of fibrosis in the T2DM group (P ¼ .16 when compared with progression in prediabetes).
Each histologic parameter was later assessed based on the proportion of patients achieving improvement of at least 1 point after 18 months of therapy (expressed as the treatment difference compared with the placebo group). As can be observed in Figure 3 , the proportion of patients with improvement in steatosis after pioglitazone therapy was similar in patients with T2DM and prediabetes (w50% for both). However, only patients with T2DM showed a significantly higher response in inflammation and ballooning when receiving pioglitazone compared with placebo (P ¼ .013 and .006, respectively). The proportion of patients with improvement in fibrosis did not achieve statistical significance in either of the groups.
Changes in Clinical Variables After Pioglitazone Treatment
Supplementary Table 1 summarizes changes in clinical variables after therapy (pioglitazone or placebo) for both patients with prediabetes and patients with T2DM. Among patients with prediabetes, there were no important changes in fasting plasma glucose or A1c levels after 18 months of pioglitazone. Changes in plasma alanine aminotransferase level were only moderate and did not reach statistical significance (-36 AE 21 vs -21 AE 27 U/L; P ¼ .07) compared with patients receiving placebo. However, use of pioglitazone among patients with prediabetes was associated with a significant reduction in fasting plasma insulin level (-8 [-14 to -3] vs -1 [-3 to 2] mU/mL; P < .001), and a significant increase in plasma adiponectin level (13.8 AE 9.6 vs -1.2 AE 2.0 mg/mL; P < .001) compared with placebo. Figure 1 . Histologic response after 18 months of pioglitazone therapy among patients with prediabetes vs T2DM. The primary outcome was improvement in the nonalcoholic fatty liver disease activity score !2 points (with improvement of at least 2 different parameters) without worsening of fibrosis. *P < .05 compared with baseline.
In patients with T2DM, pioglitazone therapy was associated with more striking improvements in fasting plasma glucose level, hemoglobin A1c level, plasma aminotransferase levels, and plasma cytokeratin-18 fragments when compared with patients with T2DM receiving placebo. However, when the interaction between pioglitazone treatment and diabetes status was formally compared (Supplementary Table 1 , last column), only plasma glucose and insulin levels after 2 hours of the OGTT showed a significant interaction between the pioglitazone effect and the presence of T2DM. No interaction was observed in any of the other clinical variables between the pioglitazone effect and the presence of T2DM. Improvements in plasma triglycerides and high-density lipoprotein-cholesterol were also of similar magnitude between patients with prediabetes and T2DM (data not shown). Of note, improvements of plasma adiponectin level after pioglitazone therapy were of similar magnitude in patients with prediabetes and T2DM (P for interaction ¼ .93).
Changes in Intrahepatic Triglyceride Content and Insulin Sensitivity After Pioglitazone Treatment
Both groups of patients showed similar reductions in intrahepatic triglyceride content by proton magnetic resonance spectroscopy after pioglitazone treatment ( Figure 4A ). Reductions in the placebo arm (both groups received a -500 kcal-deficient diet) were also similar in patients with prediabetes and T2DM, and independent of the baseline intrahepatic triglyceride content. Regarding insulin sensitivity, pioglitazone therapy was associated with a similar response in skeletal muscle and liver in patients with prediabetes and those with T2DM (note similar slopes of black lines in Figure 4B and C). Response at the level of the adipose tissue was the only one to be significantly higher in patients with T2DM compared with patients with prediabetes (P ¼ .002 for the interaction between pioglitazone therapy and diabetes status in adipose tissue insulin sensitivity expressed as suppression of FFA by insulin) ( Figure 4D ). Of note, despite patients with T2DM showing a higher improvement in suppression of FFA compared with patients with prediabetes, both groups reached a similar absolute suppression of FFA (w65%).
Among patients receiving placebo for 18 months, those with prediabetes behaved very similarly to those with T2DM independently of their different baseline values (compare grey lines with similar slopes in Figure 4A , C, and D). However, patients with T2DM (on placebo) seemed to have a more pronounced worsening of insulin sensitivity at the level of the liver ( Figure 4B ) when compared with those with prediabetes receiving placebo. However, this different progression of hepatic insulin sensitivity between groups did not reach statistical difference (P ¼ .54), nor did the worsening observed after 18 months in patients with T2DM on placebo (from 38% AE 21% to 33% AE 21%; P ¼ .13).
Pooled Analysis of Pioglitazone Trials in Nonalcoholic Steatohepatitis Including Patients With Prediabetes and Type 2 Diabetes Mellitus
Because metabolic and histologic effects were similar after 6 or 18 months of pioglitazone therapy in both of our previous randomized controlled trials in NASH, 5, 17 results from both studies also were combined for analysis. A total of 148 patients were included in this analysis (n ¼ 101 from the study by Cusi et al 5 and n ¼ 47 from the study by Belfort et al 17 ). This combined cohort included 74 patients with prediabetes and 74 with T2DM. In Supplementary Table 2 we have included their baseline clinical characteristics. As can be observed, all characteristics were similar to the ones observed in Table 1 . In Figure 5 we summarized the histologic responses among these 148 patients. Overall, we observed no significant changes compared with analyses including only 101 patients from the larger study. 5 The only difference in the combined analysis was that resolution of NASH also reached statistical significance in the prediabetes group (45% vs 21%; P ¼ .040) ( Figure 5B ).
Long-Term Effects After Pioglitazone Treatment
A total of 63 patients completed month 36 of follow-up evaluation. Of these, 34 were originally randomized to pioglitazone and therefore received 36 months of active pioglitazone (18 with T2DM and 16 with prediabetes). In Supplementary Table 3 we summarized the anthropometric, clinical, and histologic changes after 18 and 36 months of pioglitazone in these patients. As can be observed, all benefits obtained with 18 months of pioglitazone persisted after 36 months of therapy in patients with prediabetes and those with T2DM.
Discussion
Current guidelines suggest that pioglitazone improves liver histology in patients with and without T2DM with biopsy-proven NASH, and that may be used for the treatment of these patients. 7, 8 However, whether pioglitazone's metabolic and histologic effects were the same in patients with vs without T2DM was previously unknown. We believed that it was essential to compare its efficacy in patients with vs without T2DM because of the vast number of patients with prediabetes and NASH and given the significant metabolic and cardioprotective effects of pioglitazone among patients without T2DM. [9] [10] [11] [12] In the current work, 18 months of pioglitazone therapy in patients with NASH showed similar results in patients with prediabetes compared with those with T2DM, but with some important caveats related to the worse natural history of NASH in the setting of T2DM. Overall, the most important finding of the study was that patients with prediabetes and NASH benefit nearly as much from pioglitazone therapy as those with T2DM.
Patients with T2DM showed a significantly higher inflammation grade and fibrosis stage by liver histology. Moreover, after 18 months of follow-up evaluation, among those patients randomized to placebo, we observed a trend toward more progression of fibrosis in patients with T2DM when compared with those with prediabetes (P ¼ .16). These findings are in line with prior studies that have suggested that the presence of T2DM was associated with worse liver histology and a faster progression to advanced fibrosis in patients with NASH. 4, 18 Whether this worse prognosis in T2DM is a consequence of hyperglycemia per se or the result of other unknown mechanism remains a subject of heated debate. In our cohort, patients with T2DM also had more severe insulin resistance compared with patients with prediabetes, another potential factor driving the progression of NASH in T2DM. 19, 20 Because of their worse baseline liver disease and faster progression, one could have expected that patients with T2DM would benefit more from pioglitazone therapy. However, our results suggest that the response among patients with prediabetes and T2DM was similar overall. Nevertheless, some clinically meaningful differences were noted, and may deserve further exploration in larger clinical trials. Improvement in adipose tissue insulin sensitivity after pioglitazone therapy was significantly greater in patients with T2DM than in those with prediabetes, although both groups of patients had similar suppression of FFA after therapy (w65%). In line with Figure 5 . Pooled analysis of the effects of pioglitazone on (A) the primary outcome, (B) resolution of NASH, (C) steatosis, (D) inflammation, (E) ballooning, and (F) fibrosis in patients from the 2 available randomized controlled trials including patients with prediabetes and T2DM. The follow-up period was 6 months (n ¼ 47) or 18 months (n ¼ 101) based on the study population.
5,17 *P < .05 compared with baseline.
this, we observed a significantly higher resolution of NASH among patients with T2DM, as well as higher rates of patients with improvement in inflammation and ballooning. Of note, among patients taking pioglitazone, those with improvement in inflammation had a significantly greater suppression of FFA (ie, better insulin sensitivity) compared with those without changes in inflammation (increments of 29AE19% vs 13AE17%; P ¼ .022), suggesting that metabolic and histologic changes may be related. However, no such association with suppression of FFA was observed with resolution of NASH.
The reduction in the fibrosis score after 18 months of pioglitazone was similar between patients with prediabetes and T2DM (-0.4 AE 0.9 vs -0.5 AE 0.9; P ¼ .72 for both pioglitazone groups). However, when compared with placebo, it was only statistically significant in the T2DM group (-0.5 AE 0.9 vs 0.2 AE 1.2; P ¼ .042), but not in the prediabetes group (-0.4 AE 0.9 vs -0.2 AE 0.7; P ¼ .66). The most straightforward interpretation of these results is that although the regression of fibrosis with pioglitazone is the same in patients with prediabetes and those with T2DM, in the absence of treatment, the disease progresses faster in patients with T2DM, even within a relatively short period of time (ie, 18 mo). This is in agreement with prior longitudinal studies with paired biopsies, showing a faster progression among patients with T2DM. [21] [22] [23] It should be taken into account that this was a relatively small cohort of patients, and therefore the study may have been underpowered to observe smaller differences in fibrosis stage between the groups. This is especially true among patients with prediabetes because of their relatively low mean fibrosis stage at baseline, and therefore less margin for improvement. To try to overcome this limitation, we performed a pooled analysis including all patients from our 2 published randomized clinical trials with pioglitazone in NASH. 5, 17 The only significant difference was that resolution of NASH in the prediabetes group also reached statistical significance when all 148 patients were considered ( Figure 5) . Nevertheless, these results should be interpreted with caution because these 2 studies have different durations of therapy (6 and 18 mo). However, we believed this pooled analysis was appropriate because histologic changes after pioglitazone have been similar after 6, 18, 24, and even 36 months of therapy. 5, 6, 17 The role of hyperglycemia in the development and progression of NASH is unclear.
1 Pioglitazone therapy was associated with a significant improvement in glycemic control among patients with T2DM, but with no significant change in glycemia or hemoglobin A1c level in patients with prediabetes. Nevertheless, improvements in histologic parameters did occur in both groups, implying that pioglitazone's effect on glycemic control may play less of a role than treatment of insulin resistance in histologic response in NASH. In accordance with this observation, changes in hemoglobin A1c or fasting plasma glucose levels after 18 months of pioglitazone did not correlate with changes in histology among patients with or without T2DM (data not shown). However, most of the patients were well controlled at baseline (mean hemoglobin A1c among patients with T2DM was 6.9AE1.0%), and therefore to address this issue future studies will be needed.
In summary, pioglitazone therapy for 18 months is associated with an overall similar response among patients with prediabetes and T2DM. These results suggest that pioglitazone may provide the same metabolic and histologic benefits to patients with NASH and prediabetes and to those with NASH and T2DM. Greater improvements in resolution of NASH may suggest specific pioglitazone mechanisms in the T2DM population. Although the effects on fibrosis appear to be similar in both groups, pioglitazone may contribute to halting the rapid progression observed in this group. These differences will deserve further exploration in larger clinical trials. 
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